Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase IIa Study of Pharmacokinetics, Safety and Efficacy of QY201 Tablets in Adolescent Subjects With Moderate to Severe Atopic Dermatitis

NCT07712536 is registered in ClinicalTrials.gov with E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd. as lead sponsor.

NCT NCT07712536
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07712536 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase IIa Study of Pharmacokinetics, Safety and Efficacy of QY201 Tablets in Adolescent Subjects With Moderate to Severe Atopic Dermatitis
Lead sponsor
E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.
Phase
Phase 2
Overall status
Completed
Start date
June 4, 2025
Completion date
December 19, 2025
Enrollment
24 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adolescent participants with moderate to severe atopic dermatitis (ad)